Hydrophobic Vancomycin Derivatives with Improved ADME Properties:
Discovery of Telavancin Theravance, Inc., 901 Gateway Blvd., South San Francisco, CA 94080, USA (Received for publication December 19, 2003) Novel derivatives of N-decylaminoethylvancomycin (2), containing appended hydrophilic groups were synthesized and their antibacterial activity and ADME properties were evaluated. mediated amide formation, or with the resorcinol-like (R-) position of 2 using a Mannich aminomethylation reaction. These analogs retained the antibacterial activity of 2 against methicillin-resistant staphylococci and vancomycin-resistant enterococci. Compounds with a negatively charged auxiliary group also exhibited improved ADME properties relative to 2. In particular, R-phosphonomethylaminomethyl derivative 21 displayed good in vitro antibacterial activity, high urinary recovery and low distribution to liver and kidney tissues. Based on these results, 21 was advanced into development as TD-6424, and is currently in human clinical trials. The generic name telavancin has recently been approved for compound 21. (m/z=1633) we observed the fragment m/z=1305 which corresponds to loss of vancosamine plus decylaminoethyl.
We did not observe the fragment m/z=1488 corresponding to loss of unsubstituted vancosamine. This confirmed that the reductive alkylation to make 3 had taken place on the vancosamine nitrogen rather than the N-methyl-D-leucine15).
To prepare the C-terminal amides, we reacted intermediate 3 with the appropriate amine using benzotriazol-l-yloxytripyrrolidinophosphonium hexafluoro- In order to confirm the point of attachment of the aminomethyl appendage of the R-substituted compounds, a series of NMR experiments was performed on 21. In the proton spectrum of 21, the resonance corresponding to the proton attached to the 4' position of amino acid 7 was not observed. In addition, cross-peaks were observed in the 
Results and Discussion
We examined a set of compounds (4-15) with negatively charged, positively charged and neutral hydrophilic groups appended to 2 in order to assess the effect on antibacterial activity and distribution. Minimum inhibitory concentrations (MIC) for these compounds against a panel of staphylococci and enterococci including MRSA and VRE are presented in Table 2 , along with data for vancomycin and 2. Overall, the substituents had a modest effect on in vitro potency. Several compounds displayed lower MIC values than 2 against staphylococci, but no doubly substituted compound showed a significant increase in potency against VanA VRE. The most potent alanine at the C position. The MIC values for 8 were 3-to greater than 10-fold lower than 2 against staphylococci, and was equipotent with 2 against VanA VRE. Compounds with a basic nitrogen in the appended group (4, 14) were less potent than 2 against both staphylococci and VanA VRE. We selected compounds from this series to determine the effects that various substituents had on distribution and excretion. Specifically, we chose to explore compounds of varying net charge in a single-dose ADME study in rats using a dosage of 10mg/kg. The tissue distribution data determined 24 hours after dosing is shown in data suggested that the net charge of these vancomycin derivatives had a substantial impact on distribution.
Notably, the compound predicted to have zero net charge at physiological pH had the highest urinary recovery (9), while compounds with the greatest net positive charge (4 and 15) showed very low urinary clearance and high concentrations in liver or kidney tissues.
While none of these compounds proved suitable for advancement, we were encouraged that compound 9 was excreted in the urine much more efficiently than was 2. In this assay, the urinary recovery of compound 9 was equivalent to that of vancomycin (1). To follow up on the suggestion that decreasing net positive charge was critical to improving clearance and distribution properties, we prepared another set of analogs containing negatively charged groups at the C-or R-position (compounds 16-25).
As can be seen from Table 4 , this set of compounds was also very active against staphylococci in vitro. The greatest increase in potency was seen with 20 which was 3-to 5-fold more active against MSSA and MRSA than was 2.
Reduced potency was seen with the bisphosphonic acid derivative 22, and with glucamine glutamate 24, which displays 3-6 fold higher MIC values against staphylococci.
Against VanA VRE, none of the substituted compounds was more active than 2 and most were at least slightly less potent.
We examined a subset of these compounds in an intravenous single-dose ADME study in rats at 50mg/kg to determine whether the distribution and elimination properties had been improved relative to 2 by the addition of the negatively charged group. We chose 21, containing a phosphonic acid at the R-position19), 18 and 24 which contained the same N-methyl-D-glucamine glutamate substituent at the C-position and the R-position, respectively.
The tissue distribution data measured at 24 hours after dosing are displayed in 
Vancomycin hydrochloride (12g, 7.7mmol), N-Fmoc-Ndecylaminoacetaldehyde (3.2g, 7.6mmol) and DIEA (2.6ml 14.9mmol) were stirred in DMF (120ml) for 90 minutes. Sodium cyanoborohydride (1.4g, 22mmol) was added, followed by methanol (120ml) and TEA (1.8ml, 23mmol). Stirring was continued for one hour, and the methanol was removed under reduced pressure. The crude product was precipitated by addition to ether (600ml), and the solid was collected on a Buchner funnel and dried under vacuum. The crude product was purified by column chromatography on C18 reverse phase silica gel, eluting with 10, 20 and 30% ACN in water containing 0.1% TFA, followed by 70% CH3CN in water containing 0.1% TFA to elute the product. The fractions containing product were combined and lyophilized to give the TEA salt of 3 (9g, 56%).
Compound 3 (2.0g, 1.0mmol) was dissolved in DMF (10ml) and piperidine (2.0ml, 20mmol) was added. After stirring for 30 minutes, the crude deprotected product was precipitated by pouring into CH3CN (80ml) and collected by centrifuge. The pellet was washed with ether (80ml), collected by centrifuge, and the solid was dried under Table 5 . Single-dose distribution study in the rat (i.v., 50mg/kg). (15.4g, 29mmol) and DIEA (7.0ml, 40mmol). The solution was stirred for 1 hour, at which time it was poured in to water (600ml) containing K2CO3 (30g). The solution was extracted with ethyl acetate, and the organics were washed with 1N HCl in saturated NaCl, and saturated NaHCO3. The organic layer was dried over Na2SO4, and concentrated under reduced pressure. The residual oil was dissolved in methanol (100ml) and 10% Pd/C (1.6g) was added under nitrogen. 4.0N HCl in dioxane (10ml, 40mmol) was added, and the reaction was stirred under one atmosphere of hydrogen for 3 hours. The mixture was
The filtrate was concentrated under reduced pressure to approximately 30ml, and then added to CH3CN (300ml).
The precipitate was collected on a Buchner funnel and dried in vacuo to give the hydrochloride salt of 27 (6.9g, 71%) which was used without further purification. for liver and kidney distribution given are a percent of the total drug given over the study.
